Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica, NV and receives milestone payment
Galapagos NV announced that it has identified a pre-clinical compound in its alliance with Janssen Pharmaceutica NV. This achievement triggered a milestone payment of €6.6 million to Galapagos.
The pre-clinical candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. Galapagos will now start comprehensive safety evaluation to advance the compound towards Phase I clinical trials.
"Four years into the alliance, which started at the novel target stage, we are excited to have delivered the first pre-clinical candidate," said Onno van de Stolpe, CEO of Galapagos. "Our alliances with pharma provide financing to survive industry standard attrition and get a certain percentage of programs through to the clinic. In this way, Galapagos continues to build a strong R&D track record by efficiently delivering high quality results, both in its alliance and proprietary therapeutic pipelines."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.